Definitional Guide

What Is Recall Rate in Mammography?

The Abnormal Interpretation Rate (AIR): defined, calculated, and benchmarked for the breast imaging professionals who track it every year.

Last Reviewed: August 25, 2026

MQSA MetricACR Benchmark: 5-12%Per-Physician TrackingAnnual Review Required

Recall Rate in Plain Language

Recall rate, formally called the Abnormal Interpretation Rate (AIR), is the percentage of screening mammograms that result in a recommendation for additional imaging. When a radiologist interprets a screening mammogram and cannot reach a definitive conclusion without more information, they assign a BI-RADS® 0assessment and the patient is “recalled” for additional workup.

Recall rate matters because it sits at the intersection of two competing clinical pressures: the need to detect cancer early (which pushes toward recalling any ambiguous finding) and the need to avoid unnecessary patient anxiety and benign biopsies (which pushes toward recalling only high-suspicion findings). A well-calibrated recall rate reflects a radiologist who has found the right balance for their patient population.

Under MQSA, every accredited mammography facility must track recall rate per interpreting physician as part of the annual medical outcome audit, and must take corrective action when a physician’s rate falls outside the ACR’s published benchmark range.

5-12%

ACR Target Range

BI-RADS® 0

Recall Assessment

Annual

Audit Review

Per MD

Tracking Level

What Drives Recall Rate

Recall rate is influenced by both physician-level factors and facility-level operational factors.

Factors that can drive rate higher

  • Lack of comparison prior imaging
  • High proportion of first-time screeners
  • Inconsistent BI-RADS® 0 threshold across physician group
  • Limited same-day diagnostic workup capability
  • Low personal case volume (statistical instability)

Factors that can drive rate lower

  • Same-day workup that resolves findings before recall
  • Highly screened, stable patient population
  • Aggressive threshold setting below evidence-based norms
  • Under-calling findings that warrant additional workup
  • Calculation methodology that excludes eligible encounters

The Full Picture

Recall Rate Does Not Stand Alone

Recall rate should always be read alongside cancer detection rate (CDR) and PPV1. Interpreting these metrics together tells a far more complete story than any single number:

  • High recall rate + high CDR: recalling more, finding more, may be acceptable depending on degree
  • High recall rate + low CDR: recalling many patients without proportional cancer yield, most common audit concern
  • Low recall rate + high CDR: rare; efficient detection with few unnecessary recalls
  • Low recall rate + low CDR: under-detection, the most serious performance pattern

The formula that matters most: Recall rate ÷ CDR = how many recalls it takes to find one cancer.

A facility recalling 10% of patients and detecting 5 cancers per 1,000 is using recalls more efficiently than one recalling 10% and detecting 2 per 1,000. The number of recalls per cancer found is one of the most operationally meaningful ratios in breast imaging program management.

Recall Rate: Frequently Asked Questions

Detailed answers to the questions breast imaging professionals ask most often about recall rate, AIR calculation, benchmarks, and MQSA requirements.

Recall rate in mammography is the percentage of screening mammograms that result in a recommendation for additional evaluation, most commonly additional imaging views, ultrasound, or both. A patient is 'recalled' when her screening mammogram receives a BI-RADS® 0 assessment, indicating that the study is incomplete and requires further workup before a final assessment can be made. Recall rate is one of the primary performance metrics used in mammography quality assurance and is tracked as part of the MQSA-required medical outcome audit.

Abnormal Interpretation Rate (AIR) and recall rate refer to the same metric, the percentage of screening mammograms assessed as BI-RADS® 0. In MQSA and audit contexts, the precise term is AIR. 'Recall rate' is commonly used in clinical conversation and lay publications to mean the same thing, though some sources use it loosely to include all returns for additional imaging from any cause. For audit purposes, AIR is calculated as the number of BI-RADS® 0 assessments divided by the total number of screening mammograms interpreted in the audit period, expressed as a percentage.

Recall rate (AIR) = (Number of screening mammograms assessed BI-RADS® 0) ÷ (Total number of screening mammograms interpreted) × 100. For example, if a radiologist interprets 1,000 screening mammograms in a year and assigns BI-RADS® 0 to 80 of them, the recall rate for that physician is 8%. The calculation must be performed separately for each interpreting physician and for the facility as a whole. The denominator includes all screening mammograms interpreted during the period, not just those with abnormal findings.

The American College of Radiology (ACR), citing data from the Breast Cancer Surveillance Consortium (BCSC), identifies a target recall rate of 5-12% for screening mammography. A rate below 5% may indicate under-calling, the radiologist is not recommending additional workup for findings that warrant it. A rate above 12% may indicate over-calling, the radiologist is recalling patients at a higher rate without a corresponding improvement in cancer detection. Both directions represent a performance concern that warrants review under MQSA audit requirements.

A recall rate above 12% (the upper ACR benchmark) suggests that the interpreting physician or facility may be recommending additional workup more frequently than warranted. This can result in patient anxiety, unnecessary additional imaging procedures, and benign biopsies without a proportional increase in cancer detection. High recall rate is one of the most common areas flagged during MQSA medical outcome audit reviews. Common contributors include: unfamiliarity with prior comparison images, inconsistent threshold for BI-RADS® 0 among multiple interpreting physicians, lack of same-day diagnostic capability, and high proportion of first-time screeners in the patient population.

A recall rate below 5% (the lower ACR benchmark) may indicate under-detection, the radiologist is not recommending additional workup for findings that may warrant it. A low recall rate is considered a more serious performance concern than a high recall rate because it may mean cancers are being missed. MQSA audit protocols treat findings outside either end of the benchmark range with equal seriousness, but a rate below the lower threshold with a correspondingly low cancer detection rate is one of the most significant red flags in a mammography quality review.

Both. MQSA requires that medical audit metrics, including recall rate, be calculated and tracked at the individual interpreting physician level and at the aggregate facility level. Each physician must be able to see how their personal recall rate compares to internal facility averages and to published national benchmarks. This per-physician tracking is central to the audit's purpose: identifying patterns that might not be visible at the facility level but are meaningful at the individual physician level, and ensuring accountability for performance that falls outside expected ranges.

Same-day diagnostic workup, when a facility performs immediate additional imaging on a screening patient during the same visit, creates a methodological complexity in recall rate calculation. If a patient receives a BI-RADS® 0 assessment from the initial screening read but the same-day workup is completed and results in a final BI-RADS® 1 or 2, the question is whether that patient should be counted as a 'recall.' Under MQSA audit methodology, the standard approach is to count only true recalls, patients who leave the facility and are called back, as BI-RADS® 0 events. Facilities with same-day workup capabilities often need to adjust their denominator and numerator methodology to avoid artificially deflating recall rate by completing workup that would otherwise generate a separate encounter.

Recall rate and cancer detection rate (CDR) should be interpreted together, not in isolation. A radiologist with a high recall rate and a proportionally high CDR is detecting more cancers by recalling more patients, a pattern that may or may not be acceptable depending on the degree of excess recalls. A radiologist with a high recall rate and a low CDR is recalling many patients without finding a proportional number of cancers, a pattern that suggests over-calling without clinical benefit. Conversely, a low recall rate with a low CDR may indicate under-detection. The relationship between recall rate and CDR is one of the most important diagnostic signals in a well-constructed mammography audit.

When an interpreting physician's recall rate falls outside the ACR benchmark range (below 5% or above 12%), MQSA requires the facility to take corrective action. The facility must document the finding, investigate potential contributing factors, implement a corrective action plan, and monitor results. The corrective action process and its documentation must be retained and be available for FDA inspection review. Common corrective actions include case review sessions with the interpreting physician, comparison of prior images, peer review of recalled cases, and structured educational interventions.

PPV1 (Positive Predictive Value 1) measures the percentage of recall events (BI-RADS® 0 assessments) that ultimately result in a cancer diagnosis. Recall rate and PPV1 are directly related: if a radiologist has a high recall rate (recalling many patients) but a low PPV1 (few of those recalls leading to cancer), it suggests the recalls are generating a high volume of benign workup relative to cancer detection. PPV1 provides the cancer yield per recall event, essentially answering the question of whether the recalls are finding cancer at an acceptable rate.

Mammologix tracks recall rate as part of full mammography medical outcome audit support. Our audit workflow captures all BI-RADS® 0 assessments, monitors whether recalled patients complete their additional workup, correlates recall events with final outcomes and pathology results, and calculates AIR at both the physician level and facility level. We provide benchmark comparisons against ACR/BCSC targets and flag performance outside expected ranges so the facility can respond before it becomes an inspection issue. Recall rate tracking is one of the core metrics in every Mammologix audit program.

About the Author

RL
Richard D. Lippert, Jr.

Founder, President, and Chief Executive Auditor, Mammologix · Breast Imaging Operations since 1995

A registered radiologic technologist, Richard D. Lippert, Jr., Founder, President, and Chief Executive Auditor of Mammologix, has spent more than 30 years in breast imaging operations, from clinical practice and hospital radiology administration to building specialized service platforms for imaging centers nationwide. His work spans mammography tracking, lay communication, FDA/MQSA-related support, medical outcome audit, and the operational systems that help facilities stay compliant and keep patients from falling through the cracks.

View full bio →

Disclaimer

The content, articles, calculators, tools, estimates, projections, derived data, reports, and other materials provided by Mammologix, LLC, powered by I/O Trak, Inc. (“Mammologix”) are provided for informational and educational purposes only.

The information and outputs provided by Mammologix are not intended to serve as, and should not be relied upon as, medical advice, diagnosis, treatment, clinical guidance, financial advice, investment advice, tax advice, legal advice, accounting advice, or any other professional advice.

Information provided by Mammologix may relate to breast health, mammography, imaging, screening, diagnostics, clinical outcomes, healthcare topics, financial calculations, estimates, projections, or other decision-support information. However, such information should not be used to make personal medical, clinical, financial, investment, business, insurance, legal, or other important decisions without consulting an appropriate qualified professional.

Always seek the advice of a licensed physician, radiologist, healthcare provider, financial advisor, accountant, attorney, or other qualified professional with any questions you may have about a medical condition, screening recommendation, imaging result, treatment option, financial matter, or other professional decision. Never disregard professional medical, financial, legal, or other advice, or delay seeking such advice, because of something you have read, calculated, or received through Mammologix.

Any calculators, formulas, estimates, projections, derived medical outcome data, financial calculations, or other tool-generated outputs are provided as estimates only. Results may be affected by user-entered information, assumptions, formula limitations, incomplete or inaccurate data, rounding, software errors, third-party data, changing medical guidelines, changing financial conditions, changes in law or regulation, or other factors. Mammologix does not represent, warrant, or guarantee that any calculation, output, article, estimate, projection, or derived data is accurate, complete, current, reliable, suitable, or appropriate for any particular purpose.

For medical or health-related content and calculators, Mammologix does not provide medical advice, diagnosis, treatment recommendations, diagnostic interpretation, or patient-specific clinical decision-making. Mammologix content and tools are not a substitute for an in-person evaluation, professional medical consultation, diagnostic interpretation, or individualized care from a licensed healthcare provider. In the event of a medical emergency, contact emergency services or a qualified healthcare provider immediately.

For financial, business, tax, investment, or accounting-related calculators or content, Mammologix does not provide financial, investment, tax, legal, accounting, or business advice. Any outputs are estimates only, and actual results may vary materially based on personal circumstances, market conditions, taxes, fees, interest rates, inflation, risk tolerance, regulatory changes, and other factors.

Use of Mammologix content, articles, calculators, tools, and outputs is at your own risk. You are solely responsible for reviewing, verifying, and interpreting any information or results provided and for obtaining appropriate professional advice before relying on or acting upon such information.

Mammologix assumes no liability for any injury, loss, claim, damage, or expense arising from or related to the use of, reliance on, or inability to use any Mammologix content, article, calculator, tool, estimate, projection, derived data, report, or website material. To the fullest extent permitted by law, Mammologix, its owners, officers, employees, contractors, affiliates, licensors, service providers, and agents disclaim all liability for any direct, indirect, incidental, consequential, special, exemplary, punitive, financial, medical, clinical, business, or other damages arising out of or relating to the use of Mammologix materials or outputs.

The information provided by Mammologix does not establish a doctor-patient, provider-patient, radiologist-patient, financial advisor-client, attorney-client, accountant-client, fiduciary, or other professional relationship.

AI Content Disclosure

Some Mammologix content, calculations, summaries, tools, or outputs may be created, edited, generated, or assisted by artificial intelligence tools or automated systems. While Mammologix may review content for accuracy and relevance, AI-assisted or automated materials may contain errors, omissions, inaccuracies, outdated information, or outputs that are incomplete or inappropriate for a particular user, patient, circumstance, or purpose.

Users should independently verify all AI-assisted content, calculator outputs, and automated results with appropriate qualified professionals before relying on them.

Didn't find what you were looking for?

Our team has supported breast imaging centers since 1995. If it's not here, we probably know the answer.

Ask a Question →